Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB
Open Access
- 22 September 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (38), 16339-16344
- https://doi.org/10.1073/pnas.0908560106
Abstract
We describe a highly efficient use of lentiviral validation-based insertional mutagenesis (VBIM) to generate large populations of mammalian cells in which a strong promoter is inserted into many different genomic loci, causing greatly increased expression of downstream sequences. Many different selections or screens can follow, to isolate dominant mutant clones with a desired phenotypic change. The inserted promoter can be excised or silenced at will, to prove that the insertion caused the mutation. Cloning DNA flanking the insertion site identifies the locus precisely. VBIM virus particles are pseudotyped with VSV G protein, allowing efficient infection of most mammalian cell types, including non-dividing cells, and features are included that give high yields of stable virus stocks. In several different selections, useful mutants have been obtained at frequencies of approximately 10−6 or higher. We used the VBIM technique to isolate mutant human cells in which the F-box leucine-rich protein 11 (FBXL11), a histone H3K36 demethylase, is shown to be a negative regulator of NFκB. High levels of FBXL11 block the ability of NFκB to bind to DNA or activate gene expression, and siRNA-mediated reduction of FBXL11 expression has the opposite effects. The H212A mutation of FBXL11 abolishes both its histone H3K36 demethylase activity and its ability to inhibit NFκB. Thus, we have used a powerful tool for mutagenesis of mammalian cells to reveal an aspect of the complex regulation of NFκB-dependent signaling.Keywords
This publication has 24 references indexed in Scilit:
- Nuclear factor-κB in cancer development and progressionNature, 2006
- A20 inhibits NF-κB activation by dual ubiquitin-editing functionsTrends in Biochemical Sciences, 2005
- Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site PreferencesPLoS Biology, 2004
- A large-scale RNAi screen in human cells identifies new components of the p53 pathwayNature, 2004
- The IKK NF-κB system: a treasure trove for drug developmentNature Reviews Drug Discovery, 2004
- Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancerOncogene, 2003
- Transcription Start Regions in the Human Genome Are Favored Targets for MLV IntegrationScience, 2003
- CARMA1 is a critical lipid raft–associated regulator of TCR-induced NF-κB activationNature Immunology, 2002
- Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κBJCI Insight, 2001
- Forward genetics in mammaliancells: functional approaches to gene discoveryHuman Molecular Genetics, 1999